Cargando…
RET codon 609 mutations: a contribution for better clinical managing
Medullary thyroid carcinoma currently accounts for 5–8% of all thyroid cancers. The clinical course of this disease varies from extremely indolent tumors that can go unchanged for years to an extremely aggressive variant that is associated with a high mortality rate. As many as 75% of all medullary...
Autores principales: | Mian, Caterina, Sartorato, Paola, Barollo, Susi, Zane, Mariangela, Opocher, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328822/ https://www.ncbi.nlm.nih.gov/pubmed/22584703 http://dx.doi.org/10.6061/clinics/2012(Sup01)07 |
Ejemplares similares
-
Disease-modifying polymorphisms and C609Y mutation of RET associated with high penetrance of phaeochromocytoma and low rate of MTC in MEN2A
por: Speak, Rowena, et al.
Publicado: (2016) -
MON-450 Prophylactic Thyroidectomy in a Patient with Codon 891 Mutation of the RET Proto-Oncogene
por: Swami, Janya, et al.
Publicado: (2020) -
Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors
por: Barollo, Susi, et al.
Publicado: (2016) -
A Novel Somatic Mutation in the RET Proto‐oncogene in Familial Medullary Thyroid Carcinoma with a Germline Codon 768 Mutation
por: Miyauchi, Akira, et al.
Publicado: (1997) -
Germline BRCA1 Mutation Detected in a Multiple Endocrine Neoplasia Type 2 Case With RET Codon 634 Mutation
por: Sarkadi, Balázs, et al.
Publicado: (2019)